Baricitinib, methotrexate, or baricitinib plus methotrexate in patients with early rheumatoid arthritis who had received limited or no treatment with disease-modifying anti-rheumatic drugs (DMARDs): Results of the Phase 3 RA-BEGIN trial

R. Fleischmann, T. Takeuchi, D. Schlichting, W. Macias, T. Rooney, S. Gurbuz, I. Stoykov, S. Beattie, W. L. Kuo, M. Schiff, M. Dougados

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)A37
JournalRevue du Rhumatisme (Edition Francaise)
Publication statusPublished - 2016 Nov 1

ASJC Scopus subject areas

  • Rheumatology

Cite this